DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
3,500.00
-5.00 (-0.14%)
At close: Sep 11, 2026
DongKoo Bio & Pharma Revenue
DongKoo Bio & Pharma had revenue of 59.48B KRW in the quarter ending June 30, 2026, a decrease of -1.07%. This brings the company's revenue in the last twelve months to 241.43B, down -0.46% year-over-year. In the year 2025, DongKoo Bio & Pharma had annual revenue of 242.69B, down -2.64%.
Revenue (ttm)
241.43B
Revenue Growth
-0.46%
P/S Ratio
0.39
Revenue / Employee
597.61M
Employees
404
Market Cap
94.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 242.69B | -6.59B | -2.64% |
| Dec 31, 2024 | 249.27B | 33.59B | 15.57% |
| Dec 31, 2023 | 215.69B | 20.70B | 10.62% |
| Dec 31, 2022 | 194.99B | 39.84B | 25.68% |
| Dec 31, 2021 | 155.15B | 15.93B | 11.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 345.08B |
| H.PIO | 269.63B |
| Daehan Nupharm | 211.48B |
| HYUNDAI BIOLAND | 140.70B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 111.72B |
| OPTUS Pharmaceutical | 94.47B |
| KOREA PHARMA | 93.94B |
| Sam-A Pharm. | 72.28B |